Clinical trials: HSV-2
HIV Infections, Herpes Simplex
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness.
- Conditions
- HIV Infections, Herpes Simplex, Sexually Transmitted Diseases
- Trial name
- NCT00465205
- Testing
- Valacyclovir
- Where
- Peru
- Volunteers
- 20 people
- Sponsor
- University of Washington
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in…
- Trial name
- NCT06698575
- Testing
- ABI-1179
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Genital Herpes Simplex Type 2
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2…
- Trial name
- NCT05432583
- Testing
- BNT163
- Where
- 6 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HSV Infection, HIV Infection
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
The purpose of this study is to determine whether treating HSV-2 with either valacyclovir or acyclovir is more effective in suppressing HIV-1 virus levels in people co-infected with HIV-1 and HSV-2.
- Trial name
- ACV-VAL (NCT01026454)
- Testing
- acyclovir, valacyclovir
- Where
- Kenya
- Volunteers
- 32 people
- Sponsor
- University of Washington
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Stepping Stones Program for Preventing HIV Infection in Residents of Rural South African Communities
This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural…
- Trial name
- NCT00332878
- Testing
- Stepping Stones, stepping Stones short
- Where
- South Africa
- Volunteers
- 2,801 people, healthy volunteers welcome
- Sponsor
- Medical Research Council, South Africa
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.
- Trial name
- NCT00362297
- Testing
- acyclovir, valacyclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Washington
Human Immunodeficiency Virus, Herpes Simplex
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
The purpose of this study is to compare the levels of immune and inflammatory markers among HIV-1, HSV-2 co-infected adults achieving plasma HIV RNA suppression to <50 copies/mL, between those randomized to valacyclovir and…
- Trial name
- VALIANT Pilot (NCT01176409)
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Genital Herpes
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.
- Trial name
- NCT00495716
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Washington
Herpes Simplex, HIV Infections
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and…
- Trial name
- NCT00161434
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Genital Herpes
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
- Trial name
- NCT03595995
- Testing
- UB-621
- Volunteers
- 80 people
- Sponsor
- United BioPharma
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex Type Two Infection, HIV Infections
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HIV "target cells" (CD4 T cells…
- Trial name
- NCT00946556
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
HIV Infections, HIV Seronegativity
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV.
- Conditions
- HIV Infections, HIV Seronegativity, Herpes Genitalis
- Trial name
- NCT00076232
- Testing
- Acyclovir
- Where
- 3 sites in United States
- Volunteers
- 3,682 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, HSV-2 Infection
The Impact of VCT and Condom Distribution as HIV Prevention Strategies Among Youth in Kenya
The vast majority of new HIV infections occur in sub-Saharan Africa, where nearly 2 million people become infected with HIV/AIDS every year.
- Trial name
- NCT03868644
- Testing
- Voluntary Counseling and Testing for HIV (VCT), Condoms
- Volunteers
- 10,646 people
- Sponsor
- Abdul Latif Jameel Poverty Action Lab
Herpes, Herpes Simplex
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by…
- Conditions
- Herpes, Herpes Simplex, Herpes Oral, Herpes Simplex 2
- Trial name
- NCT04664127
- Testing
- Kagocel+Valacyclovir, Valacyclovir
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Nearmedic Plus LLC
Bacterial Vaginosis, Herpes Simplex Virus Type II
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2.
- Trial name
- NCT00682721
- Testing
- Valacyclovir
- Where
- United States
- Sponsor
- University of Pittsburgh
Herpes Simplex II
VivaGel™ in Healthy Young Women
The purpose of this study is to test the safety and tolerability of a medication applied vaginally twice daily in females versus placebo (inactive substance).
- Trial name
- NCT00331032
- Testing
- 3% w/w SPL7013 Gel
- Where
- 2 sites in United States, Kenya
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Simplex Virus 2
HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population
This study is designed to compare the performance of the Focus Diagnostics' HerpeSelect® Express, a Herpes Simplex Virus 2 Rapid Test, to a currently marketed device.
- Trial name
- NCT00655434
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Focus Diagnostics, Inc.
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington